Control of cell cycle progression in human mesothelioma cells treated with gamma interferon

Oncogene. 2001 Mar 1;20(9):1085-93. doi: 10.1038/sj.onc.1204199.

Abstract

Recombinant human interferon gamma (r-hu-IFNgamma) exerts both antitumoral activity in the early stages of human malignant mesothelioma and a cytostatic effect in human mesothelioma (HM) cell lines in vitro. The antiproliferative effect of interferons (IFNs) reported in a variety of cells has been attributed to several mechanisms. In order to progress in the understanding of HM cell growth modulation by r-hu-IFNgamma, modifications of cell cycle progression and expression of key cell cycle regulator proteins in response to r-hu-IFNgamma were examined. Nine HM cell lines were studied, including one resistant to the antiproliferative effect of r-hu-IFNgamma. Except in the resistant cell line r-hu-IFNgamma produced an arrest in the G1 and G2-M phases of the cell cycle, associated with a reduction in both cyclin A and cyclin dependent kinase inhibitors (CDKIs) expression. Moreover cyclin B1/cdc2 activity was decreased. The present study provides the first evidence of a G2-arrest in r-hu-IFNgamma-treated HM cell lines and indicates that HM cell lines, despite their tumorigenic origin still support cell cycle control. The cell cycle arrest induced by r-hu-IFNgamma seems to depend on cyclin regulation through p21(WAF1/CIP1)- and p27(Kip1)-independent mechanisms and is not directly related to the induced DNA damage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Blotting, Western
  • Cell Cycle Proteins*
  • Cell Division
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclin-Dependent Kinase Inhibitor p27
  • Cyclin-Dependent Kinases / metabolism
  • Cyclins / metabolism*
  • Cytogenetic Analysis
  • DNA Damage / drug effects
  • Electrophoresis, Polyacrylamide Gel
  • Enzyme Induction
  • Flow Cytometry
  • G2 Phase / drug effects*
  • G2 Phase / physiology
  • Humans
  • Interferon-gamma / pharmacology*
  • Mesothelioma / drug therapy*
  • Mesothelioma / metabolism
  • Mesothelioma / pathology
  • Microtubule-Associated Proteins / metabolism
  • Pleural Neoplasms / drug therapy*
  • Pleural Neoplasms / metabolism
  • Pleural Neoplasms / pathology
  • Protein Kinases / metabolism
  • Recombinant Proteins
  • Thymidine / chemistry
  • Transfection
  • Tumor Cells, Cultured
  • Tumor Suppressor Protein p53 / physiology
  • Tumor Suppressor Proteins*

Substances

  • Antineoplastic Agents
  • CDKN1A protein, human
  • Cell Cycle Proteins
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins
  • Microtubule-Associated Proteins
  • Recombinant Proteins
  • Tumor Suppressor Protein p53
  • Tumor Suppressor Proteins
  • Cyclin-Dependent Kinase Inhibitor p27
  • Interferon-gamma
  • Protein Kinases
  • Cyclin-Dependent Kinases
  • Thymidine